Inflammatory profile in LRRK2-associated prodromal and clinical PD

Table 1 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts IPD, PD_LRRK2 and CON stratified by gender

	Female N = 211			Male N = 208			Female				Male
	IPD N = 49	PD_LRRK2 N = 73	CON N = 89	IPD N = 95	PD_LRRK2 N = 69	CON N = 44	p value IPD PD_LRRK2 CON	p value Post hoc IPD CON	p value Post hoc PD_LRRK2 CON	p value Post hoc IPD PD_LRRK2	p value IPD PD_LRRK2 CON	p value Post hoc IPD CON	p value Post hoc PD_LRRK2 CON	p value Post hoc IPD PD_LRRK2
Age Years	68 46–83	67 35–89	57 18–83	69 46–80	65 36–88	58 28–83	0.001	0.001	0.001	0.999	0.001	0.001	0.012	0.204
Age at onset Years	60 39–77	59 29–76		61 39–75	54 23–82					0.280				0.001
Disease duration Years	7 1–20	10 1–25		7 1–21	11 1–34					0.003				0.001
UPDRS-III	26 6–64	18 2–82	0 0–9	28 9–61	19 1–70	0 0–8	0.001	0.001	0.001	0.379	0.001	0.001	0.001	0.001
HY	2 1–4	2 1–5		2 1–4	2 1–5					0.544				0.889
MoCA	27 11–30	25 6–30	27 17–30	27 13–30	24 5–30	27 17–30	0.001	0.999	0.001	0.014	0.001	0.999	0.002	0.001
RBD Questionnaire	3 0–11	3 0–11	1 0–13	4 0–13	3 0–12	1 0–11	0.001	0.001	0.001	0.941	0.001	0.001	0.017	0.009
ESS	9 1–18	6 0–24	6 0–15	10 0–23	8 0–24	6 0–14	0.002	0.002	0.999	0.024	0.001	0.001	0.246	0.057
SCOPA-AUT	15 2–36	15 0–45	7 0–41	13 0–40	12 0–51	6 0–30	0.001	0.001	0.001	0.999	0.001	0.001	0.001	0.999
Regular anti-inflammatory medication (% of individuals)	12.2	10.3	1.2	10.5	3.1	0.0	0.022	0.010	0.023	0.772	0.032	0.033	0.522	0.125

Data are presented as median with range. p values reflect results from Kruskal-Wallis test and, in case of significant differences between the three cohorts, pair-wise post hoc Dunn Test including correction for multiple comparisons. Statistical analysis for the intake of anti-inflammatory medication was done using chi-square test
IPD patients with idiopathic Parkinson’s disease, PD _LRRK2 patients with Parkinson’s disease carrying a LRRK2 mutation, NMC _LRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale

ISSN: 1742-2094